vs
Esperion Therapeutics, Inc.（ESPR）与USA Compression Partners, LP（USAC）财务数据对比。点击上方公司名可切换其他公司
USA Compression Partners, LP的季度营收约是Esperion Therapeutics, Inc.的1.5倍（$252.5M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 2.7%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 4.9%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
USA Compression Partners, LP是一家总部位于美国的天然气压缩服务供应商，服务覆盖油气行业上游、中游及下游领域，提供定制化压缩系统、设备维护与运营支持，助力天然气生产、加工和运输环节高效运转。
ESPR vs USAC — 直观对比
营收规模更大
USAC
是对方的1.5倍
$168.4M
营收增速更快
ESPR
高出141.0%
2.7%
两年增速更快
ESPR
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $252.5M |
| 净利润 | — | $27.8M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 30.3% |
| 净利率 | — | 11.0% |
| 营收同比 | 143.7% | 2.7% |
| 净利润同比 | — | 9.1% |
| 每股收益（稀释后） | $0.32 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRUSAC
| Q4 25 | $168.4M | $252.5M | ||
| Q3 25 | $87.3M | $250.3M | ||
| Q2 25 | $82.4M | $250.1M | ||
| Q1 25 | $65.0M | $245.2M | ||
| Q4 24 | $69.1M | $245.9M | ||
| Q3 24 | $51.6M | $240.0M | ||
| Q2 24 | $73.8M | $235.3M | ||
| Q1 24 | $137.7M | $229.3M |
净利润ESPRUSAC
| Q4 25 | — | $27.8M | ||
| Q3 25 | $-31.3M | $34.5M | ||
| Q2 25 | $-12.7M | $28.6M | ||
| Q1 25 | $-40.5M | $20.5M | ||
| Q4 24 | — | $25.4M | ||
| Q3 24 | $-29.5M | $19.3M | ||
| Q2 24 | $-61.9M | $31.2M | ||
| Q1 24 | $61.0M | $23.6M |
营业利润率ESPRUSAC
| Q4 25 | 50.6% | 30.3% | ||
| Q3 25 | -11.4% | 33.5% | ||
| Q2 25 | 8.6% | 30.6% | ||
| Q1 25 | -34.0% | 28.3% | ||
| Q4 24 | -6.4% | 30.3% | ||
| Q3 24 | -31.0% | 31.5% | ||
| Q2 24 | 3.5% | 32.9% | ||
| Q1 24 | 52.5% | 29.2% |
净利率ESPRUSAC
| Q4 25 | — | 11.0% | ||
| Q3 25 | -35.9% | 13.8% | ||
| Q2 25 | -15.4% | 11.4% | ||
| Q1 25 | -62.2% | 8.4% | ||
| Q4 24 | — | 10.3% | ||
| Q3 24 | -57.2% | 8.1% | ||
| Q2 24 | -83.9% | 13.3% | ||
| Q1 24 | 44.3% | 10.3% |
每股收益（稀释后）ESPRUSAC
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $8.6M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $-302.0M | — |
| 总资产 | $465.9M | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRUSAC
| Q4 25 | $167.9M | $8.6M | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | $2.0K | ||
| Q1 25 | $114.6M | $2.0K | ||
| Q4 24 | $144.8M | $14.0K | ||
| Q3 24 | $144.7M | $79.0K | ||
| Q2 24 | $189.3M | $9.0K | ||
| Q1 24 | $226.6M | $8.0K |
总债务ESPRUSAC
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.5B |
股东权益ESPRUSAC
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | — | ||
| Q2 25 | $-433.5M | — | ||
| Q1 25 | $-426.2M | — | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | — | ||
| Q2 24 | $-344.2M | — | ||
| Q1 24 | $-294.3M | — |
总资产ESPRUSAC
| Q4 25 | $465.9M | $2.6B | ||
| Q3 25 | $364.0M | $2.7B | ||
| Q2 25 | $347.1M | $2.7B | ||
| Q1 25 | $324.0M | $2.7B | ||
| Q4 24 | $343.8M | $2.7B | ||
| Q3 24 | $314.1M | $2.8B | ||
| Q2 24 | $352.3M | $2.8B | ||
| Q1 24 | $373.1M | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $139.5M |
| 自由现金流经营现金流 - 资本支出 | — | $87.7M |
| 自由现金流率自由现金流/营收 | — | 34.8% |
| 资本支出强度资本支出/营收 | 0.0% | 20.5% |
| 现金转化率经营现金流/净利润 | — | 5.02× |
| 过去12个月自由现金流最近4个季度 | — | $277.0M |
8季度趋势，按日历期对齐
经营现金流ESPRUSAC
| Q4 25 | $45.2M | $139.5M | ||
| Q3 25 | $-4.3M | $75.9M | ||
| Q2 25 | $-31.4M | $124.2M | ||
| Q1 25 | $-22.6M | $54.7M | ||
| Q4 24 | $-35.0M | $130.2M | ||
| Q3 24 | $-35.3M | $48.5M | ||
| Q2 24 | $-7.2M | $96.7M | ||
| Q1 24 | $53.8M | $65.9M |
自由现金流ESPRUSAC
| Q4 25 | — | $87.7M | ||
| Q3 25 | — | $51.9M | ||
| Q2 25 | — | $101.1M | ||
| Q1 25 | — | $36.3M | ||
| Q4 24 | — | $101.2M | ||
| Q3 24 | $-35.5M | $19.8M | ||
| Q2 24 | $-7.3M | $48.2M | ||
| Q1 24 | $53.8M | $-32.7M |
自由现金流率ESPRUSAC
| Q4 25 | — | 34.8% | ||
| Q3 25 | — | 20.7% | ||
| Q2 25 | — | 40.4% | ||
| Q1 25 | — | 14.8% | ||
| Q4 24 | — | 41.1% | ||
| Q3 24 | -68.7% | 8.2% | ||
| Q2 24 | -9.9% | 20.5% | ||
| Q1 24 | 39.0% | -14.3% |
资本支出强度ESPRUSAC
| Q4 25 | 0.0% | 20.5% | ||
| Q3 25 | 0.0% | 9.6% | ||
| Q2 25 | 0.0% | 9.3% | ||
| Q1 25 | 0.0% | 7.5% | ||
| Q4 24 | 0.0% | 11.8% | ||
| Q3 24 | 0.3% | 12.0% | ||
| Q2 24 | 0.1% | 20.6% | ||
| Q1 24 | 0.1% | 43.0% |
现金转化率ESPRUSAC
| Q4 25 | — | 5.02× | ||
| Q3 25 | — | 2.20× | ||
| Q2 25 | — | 4.35× | ||
| Q1 25 | — | 2.66× | ||
| Q4 24 | — | 5.12× | ||
| Q3 24 | — | 2.51× | ||
| Q2 24 | — | 3.10× | ||
| Q1 24 | 0.88× | 2.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
USAC
| Revenue From Contract Operations Excluding Revenue From Related Party | $231.7M | 92% |
| Entities Affiliated With Energy Transfer LP | $16.6M | 7% |
| Transferred At Point In Time | $5.4M | 2% |
